Format
Sort by
Items per page

Send to

Choose Destination

Links from PubMed

Items: 1 to 20 of 34

1.

Validity of the MoCA and MMSE in the detection of MCI and dementia in Parkinson disease.

Hoops S, Nazem S, Siderowf AD, Duda JE, Xie SX, Stern MB, Weintraub D.

Neurology. 2009 Nov 24;73(21):1738-45. doi: 10.1212/WNL.0b013e3181c34b47.

3.

A controlled trial of antidepressants in patients with Parkinson disease and depression.

Menza M, Dobkin RD, Marin H, Mark MH, Gara M, Buyske S, Bienfait K, Dicke A.

Neurology. 2009 Mar 10;72(10):886-92. doi: 10.1212/01.wnl.0000336340.89821.b3. Epub 2008 Dec 17.

4.

Atomoxetine for the treatment of executive dysfunction in Parkinson's disease: a pilot open-label study.

Marsh L, Biglan K, Gerstenhaber M, Williams JR.

Mov Disord. 2009 Jan 30;24(2):277-82. doi: 10.1002/mds.22307.

5.

Comparison of desipramine and citalopram treatments for depression in Parkinson's disease: a double-blind, randomized, placebo-controlled study.

Devos D, Dujardin K, Poirot I, Moreau C, Cottencin O, Thomas P, Destée A, Bordet R, Defebvre L.

Mov Disord. 2008 Apr 30;23(6):850-7. doi: 10.1002/mds.21966.

PMID:
18311826
6.

Atomoxetine improved response inhibition in adults with attention deficit/hyperactivity disorder.

Chamberlain SR, Del Campo N, Dowson J, Müller U, Clark L, Robbins TW, Sahakian BJ.

Biol Psychiatry. 2007 Nov 1;62(9):977-84. Epub 2007 Jul 17.

PMID:
17644072
7.

Norepinephrine: The redheaded stepchild of Parkinson's disease.

Rommelfanger KS, Weinshenker D.

Biochem Pharmacol. 2007 Jul 15;74(2):177-90. Epub 2007 Feb 3. Review.

PMID:
17416354
8.

An examination of executive dysfunction associated with frontostriatal circuitry in Parkinson's disease.

Zgaljardic DJ, Borod JC, Foldi NS, Mattis PJ, Gordon MF, Feigin A, Eidelberg D.

J Clin Exp Neuropsychol. 2006 Oct;28(7):1127-44.

9.

Discriminative-stimulus, self-reported, performance, and cardiovascular effects of atomoxetine in methylphenidate-trained humans.

Lile JA, Stoops WW, Durell TM, Glaser PE, Rush CR.

Exp Clin Psychopharmacol. 2006 May;14(2):136-47.

PMID:
16756417
10.

Evaluation of outcomes with citalopram for depression using measurement-based care in STAR*D: implications for clinical practice.

Trivedi MH, Rush AJ, Wisniewski SR, Nierenberg AA, Warden D, Ritz L, Norquist G, Howland RH, Lebowitz B, McGrath PJ, Shores-Wilson K, Biggs MM, Balasubramani GK, Fava M; STAR*D Study Team.

Am J Psychiatry. 2006 Jan;163(1):28-40.

PMID:
16390886
11.

Modafinil for daytime somnolence in Parkinson's disease: double blind, placebo controlled parallel trial.

Ondo WG, Fayle R, Atassi F, Jankovic J.

J Neurol Neurosurg Psychiatry. 2005 Dec;76(12):1636-9.

12.

Augmentation with open-label atomoxetine for partial or nonresponse to antidepressants.

Carpenter LL, Milosavljevic N, Schecter JM, Tyrka AR, Price LH.

J Clin Psychiatry. 2005 Oct;66(10):1234-8.

PMID:
16259536
13.

Provisional diagnostic criteria for depression in Parkinson's disease: report of an NINDS/NIMH Work Group.

Marsh L, McDonald WM, Cummings J, Ravina B; NINDS/NIMH Work Group on Depression and Parkinson's Disease.

Mov Disord. 2006 Feb;21(2):148-58. Review.

PMID:
16211591
14.

Antidepressant studies in Parkinson's disease: a review and meta-analysis.

Weintraub D, Morales KH, Moberg PJ, Bilker WB, Balderston C, Duda JE, Katz IR, Stern MB.

Mov Disord. 2005 Sep;20(9):1161-9. Review.

15.

Recognition and treatment of depression in Parkinson's disease.

Weintraub D, Moberg PJ, Duda JE, Katz IR, Stern MB.

J Geriatr Psychiatry Neurol. 2003 Sep;16(3):178-83.

PMID:
12967062
17.
18.

Randomized trial of modafinil for treating subjective daytime sleepiness in patients with Parkinson's disease.

Adler CH, Caviness JN, Hentz JG, Lind M, Tiede J.

Mov Disord. 2003 Mar;18(3):287-93.

PMID:
12621632
19.

Effect of reboxetine on depression in Parkinson's disease patients.

Lemke MR.

J Clin Psychiatry. 2002 Apr;63(4):300-4.

PMID:
12000202
20.

Provisional diagnostic criteria for depression of Alzheimer disease.

Olin JT, Schneider LS, Katz IR, Meyers BS, Alexopoulos GS, Breitner JC, Bruce ML, Caine ED, Cummings JL, Devanand DP, Krishnan KR, Lyketsos CG, Lyness JM, Rabins PV, Reynolds CF 3rd, Rovner BW, Steffens DC, Tariot PN, Lebowitz BD.

Am J Geriatr Psychiatry. 2002 Mar-Apr;10(2):125-8.

PMID:
11925273

Supplemental Content

Support Center